Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog


Channel Description:

Daily news and press releases on companies.
    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Publisher's, 'Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted pipeline therapeutics.

    The report provides comprehensive information on the Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Request for Sample: http://www.reportsweb.com/Ephrin-Type-A-Receptor-2-(Epithelial-Cell-Kinase-or-Tyrosine-Protein-Kinase-Receptor-ECK-or-EPHA2-or-EC-2.7.10.1)---Pipeline-Review,-H1-2016

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1)
    - The report reviews Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Inquire for Discount: http://www.reportsweb.com/inquiry&RW0001347482/discount

    About Us
    ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Phone: +1-646-491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Publisher's, 'Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted pipeline therapeutics.

    The report provides comprehensive information on the Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Request for Sample: http://www.reportsweb.com/Ephrin-Type-B-Receptor-4-(Hepatoma-Transmembrane-Kinase-or-Tyrosine-Protein-Kinase-TYRO11-or-EPHB4-or-EC-2.7.10.1)---Pipeline-Review,-H1-2016

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1)
    - The report reviews Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Inquire for Discount: http://www.reportsweb.com/inquiry&RW0001347505/discount

    About Us
    ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Phone: +1-646-491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Office stationery and supply products segment is a broad category of the global office stationery, supply, and services market. Office stationery and supply products contribute approximately 80% of the revenue of the overall market.

    Publisher's analysts forecast the office stationery and supplies market in the US to grow at a CAGR of 0.25% during the period 2016-2020.

    Covered in this report
    The report covers the present scenario and the growth prospects of the office stationery and supplies market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the B2B retail sales of office stationery and supply products to individual offices in the US.
    For more information about this report: http://www.reportsweb.com/office-stationery-and-supplies-market-in-the-us-2016-2020
    The market is divided into the following segments based on geography:
    - Far West
    - Great Lakes
    - Mideast
    - New England
    - Plains
    - Rocky Mountain
    - Southeast
    - Southwest

    Publisher's report, Office Stationery and Supplies Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

    Key vendors
    - Costco Wholesale
    - Office Depot
    - Staples
    - Target
    - Walmart

    Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001362557/sample

    Other prominent vendors
    - 3M
    - Amazon
    - Alibaba
    - Best Buy
    - FedEx Office

    Market driver
    - Growth of e-commerce through increased internet and smartphone penetration
    - For a full, detailed list, view our report

    Market challenge
    - Environmental concerns regarding biodegradation and deforestation
    - For a full, detailed list, view our report

    Market trend
    - Technological advancement and product innovation
    - For a full, detailed list, view our report

    Key questions answered in this report
    - What will the market size be in 2020 and what will the growth rate be?
    - What are the key market trends?
    - What is driving this market?
    - What are the challenges to market growth?
    - Who are the key vendors in this market space?
    - What are the market opportunities and threats faced by the key vendors?
    - What are the strengths and weaknesses of the key vendors?

    You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

    Inquire for Report at http://www.reportsweb.com/inquiry&RW0001362557/buying




    Priya Sisodia
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) 4G Commercial Strategies in Asia-Pacific' report provides an overview of the variety of commercialization strategies operators have adopted in APAC, including analysis of the major components.

    It consists of:
    -Overview of 4G market trends in APAC highlighting adoption, smartphone sales and frequency spectrum usage.
    -Overview of the key components of mobile 4G commercialization strategies covering client segmentation, products, pricing, promotion and distribution strategies.
    -Analysis and overview of select operators

     



    in APAC which have or will launch mobile 4G services.
    -Key Finding
    s from commercialization strategies in the region and a set of recommendations for telecom operators and network vendors.


    Report Summary

    Availability of 4G services is disparately distributed between developed and emerging countries in Asia-Pacific region. However, 4G has been rapidly gaining ground across the region with the rising demand for data services. In increasing network capacity, mobile operators face challenges such as the shortage of spectrum and high cost of network deployment. The key question for operators is how to achieve their ROI objectives and staying competitive in the marketplace.
    Operators in the APAC region have been using a variety of commercialization strategies including client segmentation, devices availability, appropriate pricing strategies, effective promotional campaigns to raise awareness and optimal use of various distribution networks. Operators in emerging countries like India and Malaysia are focusing on affordability of 4G services in order to accelerate adoption. On the other hand, operators in developed markets aim to provide advanced services such as M2M/IoT and other data intensive applications to boost 4G adoption

    Request for Sample @ http://www.reportsweb.com/inquiry&RW0001233068/sample
    Key Finding

    -Total 4G mobile subscriptions in Asia-Pacific is expected to increase by a CAGR of 25.1% between 2015 and 2020. The success of operators to realize returns on investment for 4G services relies on their underlying commercialization strategy.
    -Operators in emerging countries can benefit by offering cost-effective services to the large young population and residential segment. Operators in developed markets should targeting tech-savvy customers with larger data volume bundles, discounted OTT and VAS services and enterprise services (e.g., IoT/M2M and access to data networks).
    -Operators in developed markets offer larger data allowances, and in many cases, unlimited data with free calls and text messages. In emerging markets, operators focus on accelerating adoption by bundling devices with LTE plans as affordability remains a key hurdle in these markets.
    -Distribution strategies are aimed at leveraging existing direct and indirect sales channels to drive 4G uptake. Operators use both their physical retail stores and online websites to drive adoption of 4G service. Physical stores are important to drive take up particularly in rural areas due to tech support available for the population.

    Inquire for Discount @ http://www.reportsweb.com/inquiry&RW0001233068/discount
    Reason to Buy

    -Gain understanding of successful 4G commercial strategies utilised by telcos in key APAC markets.
    -Align product portfolios by selecting suitable commercial strategies needed to ensure faster up-take of 4G services.
    -Quicken the decision-making process by understanding the strategies which underpin commercial 4G strategies in terms of client segmentation, products, pricing, promotion and distribution.
    -Gain understanding of the competitive landscape, to strengthen market positioning and competitiveness.


    About Us
    ReportsWeb is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Call: +1-646- 491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646- 491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Publisher's, 'Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted pipeline therapeutics.

    The report provides comprehensive information on the Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Request for Sample: http://www.reportsweb.com/Fibroblast-Growth-Factor-Receptor-1-(Basic-Fibroblast-Growth-Factor-Receptor-1-or-Fms-Like-Tyrosine-Kinase-2-or-Proto-Oncogene-c-Fgr-or-CD331-or-FLT2-or-FGFR1-or-EC-2.7.10.1)---Pipeline-Review,-H1-2016

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1)
    - The report reviews Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Inquire for Discount: http://www.reportsweb.com/inquiry&RW0001347477/discount

    About Us
    ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Phone: +1-646-491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) A power cable is primarily an assembly of one or more electrical conductors, usually held together by an overall sheath. Power cables are used for transmission and, in some cases, distribution of large quantities of electrical power. Power cables have three basic components, namely, conductor, insulation, and protective covering or sheath. Other than the three basic components, the cable can also consist of bedding and beading/armoring depending on its architecture.

    Publisher's analysts forecast the power cables market in China to grow at a CAGR of 6.10% during the period 2016-2020.
    For more information about this report: http://www.reportsweb.com/power-cable-market-in-china-2016-2020
    Covered in this report
    The report covers the present scenario and the growth prospects of the power cables market in China for 2016-2020. The market size has been estimated on both the demand side as well as supply side. For calculation purposes, 1 circuit kilometer = 0.5 kilometers have been considered.

    The market is divided into the following segments based on products:
    - Distribution
    - Transmission

    Publisher's report, Power Cables Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

    Key vendors
    - Far East Cable Company
    - Jiangnan Group
    - Nexans
    - Prysmian
    - Shandong Wanda Cable

    Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001362558/sample

    Other prominent vendors
    - Anhui Hualing Cable Group
    - Baosheng Group
    - General Cable
    - Havells
    - Henan Huadong Cable
    - Henan Jinshui Cable Group
    - Henan Tano Cable
    - Jiangsu Shangshang Cable Group Co. Ltd.
    - Jiangyang Cable
    - Luoyang Da Yuan Cable Factory Co. Ltd.
    - Shanghai Shenghua Cable Group
    - Suli Group
    - TBEA Shandong Luneng Taishan Cable
    - Wanma Cable
    - Zhengzhou Yifang Cable

    Market driver
    - Smart grid implementation
    - For a full, detailed list, view our report

    Market challenge
    - Wind power curtailment challenges
    - For a full, detailed list, view our report

    Market trend
    - Renewable cable protection systems
    - For a full, detailed list, view our report

    Key questions answered in this report
    - What will the market size be in 2020 and what will the growth rate be?
    - What are the key market trends?
    - What is driving this market?
    - What are the challenges to market growth?
    - Who are the key vendors in this market space?
    - What are the market opportunities and threats faced by the key vendors?
    - What are the strengths and weaknesses of the key vendors?

    You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

    Inquire for Report at http://www.reportsweb.com/inquiry&RW0001362558/buying



    Priya Sisodia
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) 4G Commercial Strategies in Africa and the Middle East' report provides an overview of the variety of commercialization strategies operators have adopted in AME, including analysis of the major components.

    It consists of:

    - Overview of 4G market trends in AME and factors including adoption, smartphone sales and frequency spectrum usage.
    - Overview of the key components of mobile 4G commercialization strategies covering client segmentation, products, pricing, promotion and distribution strategies.
    - Analysis and

     



    overview of select operators in AME which have or will launch mobile 4G services.
    - Key findings from commercialization strategies in the region and a set of recommendations for telecom operators and network vendors.

    Report Summary

    Availability of 4G services has been increasing rapidly over the past few years across Africa and the Middle East (AME). This follows significant research, scoping and lobbying efforts by operators on issues such as spectrum allocations and the viability of 4G services in the local market. Such operators have or will use a variety of commercialization strategies determined by market demographics for client segmentation, suitable devices, appropriate pricing strategies, effective promotional campaigns to raise awareness and optimal use of distribution networks. As a result, over the next five years, growth in 4G subscriptions will largely be driven by continued adoption across Middle Eastern countries (e.g., Saudi Arabia, UAE, Kuwait and Qatar) and in relatively developed African telecoms markets, such as South Africa and Nigeria. In less developed markets such as Democratic Republic of Congo, 4G network rollout will be selective with initial rollout expected in high population density areas

    Request for Sample @ http://www.reportsweb.com/inquiry&RW0001149174/sample
    Key Findings

    - In the MENA region, operators are increasingly developing online stores and marketing OTT services through OTT partnerships to increase 4G-compatible smartphones and increase data bundle adoption. In sub-Saharan Africa, operators largely rely on informal distribution networks to reach their addressable market and offer promotional data bundles for specific services (e.g., social network data bundles), this will support 4G uptake over the next five years.
    - In the battle for market share, the success of an operator to acquire 4G subscriptions in AME is also dependent on marketing their unique selling points and service strengths.
    - For example, incumbents with large networks market their quality of service capabilities (e.g., Turk Telekom), while operators with lower market share in terms of subscribers can promote their value-for money focus (e.g., MTN South Africa).
    - Operators across AME are however facing a number of challenges related to their 4G strategies. Key challenges, particularly in several African markets, include the high cost of network rollouts. While in more developed telecoms markets in terms of smartphone adoption, such as the GCC, operators are increasingly concerned with spectrum allocations to deliver 4G speeds and coverage effectively.

    Inquire for Discount @ http://www.reportsweb.com/inquiry&RW0001149174/discount
    Reason to Buy

    - Gain understanding of successful 4G commercial strategies utilized by telcos in key AME markets. Align product portfolios by selecting suitable commercial strategies needed to ensure the optimal up-take of 4G services in the local market.
    - Quicken the decision-making process by understanding the strategies which underpin commercial 4G strategies in terms of client segmentation, products, pricing, promotion and distribution.
    - Gain understanding of the competitive landscape, to strengthen your positioning in the market versus operators.
    About Us
    ReportsWeb is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Call: +1-646- 491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646- 491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Publisher's, 'Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted pipeline therapeutics.

    The report provides comprehensive information on the Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Request for Sample: http://www.reportsweb.com/Fibroblast-Growth-Factor-Receptor-2-(Keratinocyte-Growth-Factor-Receptor-or-K-Sam-or-KGFR-or-CD332-or-FGFR2-or-EC-2.7.10.1)---Pipeline-Review,-H1-2016

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1)
    - The report reviews Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Inquire for Discount: http://www.reportsweb.com/inquiry&RW0001347478/discount

    About Us
    ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Phone: +1-646-491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Sample/TOC request, please email : phoebe@qyresearch.com

    Report summery

    The report provides a basic overview of the Forged Steel Grinding Media industry including definitions, classifications, applications and industry chain structure.

    Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand figures, cost, price, revenue and gross margins.

    The report then analyzes the global Forged

     



    Steel Grinding Media market size (volume and value), and the sales segment market is also discussed by product type, application and region.

    The major Forged Steel Grinding Media market (including USA, Europe, China, Japan, etc.) is analyzed, data including: market size, import and export, sale segment market by product type and application. Then we forecast the 2016-2021 market size of Forged Steel Grinding Media.

    The report focuses on global major leading companies providing information such as company profiles, sales, sales revenue, market share and contact information. Then the Forged Steel Grinding Media OEM market and Forged Steel Grinding Media production market status is discussed.

    Finally the marketing, feasibility of new investment projects are assessed and overall research conclusions offered.



    Players covering

    Windsor Steelballs

    Magotteaux

    FOX Industries

    Scaw Metals Group

    Union Process

    Arrium Limited

    Energosteel

    Oriental

    TOYO Grinding Ball Co.Ltd

    Metso

    AIA Engineering

    Technocon Engineers

    Mufaddal International

    Zhangqiu Taitou Special Steel Ball Factory

    JINAN HAOYANG CASTING & FORGING CO.,LTD

    ...

    Part of the Catalog for reference:

    1 Forged Steel Grinding Media Overview

    1.1 Product Overview and Scope of Forged Steel Grinding Media

    1.2 Classification of Forged Steel Grinding Media

    1.2.1 Type I

    1.2.2 Type II

    1.2.3 Type III

    1.3 Application of Forged Steel Grinding Media

    1.3.1 Application 1

    1.3.2 Application 2

    1.3.3 Application 3

    1.4 Forged Steel Grinding Media Market by Regions

    1.4.1 USA Status and Prospect (2011-2021)

    1.4.2 China Status and Prospect (2011-2021)

    1.4.3 Europe Status and Prospect (2011-2021)

    1.4.4 Japan Status and Prospect (2011-2021)

    1.4.5 India Status and Prospect (2011-2021)

    1.4.6 Southeast Asia Status and Prospect (2011-2021)

    1.5 Global Market Size (Value and Volume) of Forged Steel Grinding Media (2011-2021)

    1.5.1 Global Forged Steel Grinding Media Sales and Growth Rate (2011-2021)

    1.5.2 Global Forged Steel Grinding Media Revenue and Growth Rate (2011-2021)



    2 Global Forged Steel Grinding Media Competition by Manufacturers, Type and Application

    2.1 Global Forged Steel Grinding Media Market Competition by Manufacturers

    ...

    Contact me:

    QYRESEARCH CO., LTD

    VILI International Building No.167 Linhe West Road Tianhe District Guangzhou China

    Phoebe Lee - QYResearch Report Global Sales

    Email: phoebe@qyresearch.com phoebe@qyresearchglobal.com

    Web: http://qyresearchglobal.com/ http://qyresearcheurope.com/




    qyresearch global
    862086655165
    phoebe@qyresearch.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Carrier digital communications: Agility in innovative use cases will maximize service provider opportunities' report by Pyramid Research describes the state of the carrier digital communications market, analyzes the market drivers and details a number of industry and service provider initiatives that highlight how technologies from VoLTE to Wi-Fi Calling and WebRTC is moving towards commercialization.

    The report comprises of the following sections:
    - Section 1: The carrier digital communications imperative
    - Section

     



    2: Digital communications technology trends
    - Section 3: Digital communications carrier deployments and case studies
    - Section 4: What's next for digital communications?
    - Section 5: Key findings & recommendations
    Report Summary
    Over the top (OTT) messaging leaders are rapidly evolving their key mobile messaging application interfaces to new voice and video communications, with revenue dilution implications for carriers worldwide. The progress made in mobile IP voice and video this year alone from key OTT players such as Facebook and Google is a clear indication of heightened mobile communications competitive pressure from these new players in 2016 and beyond. Operator have picked up the pace with the deployment of new digital communications technologies such as VoLTE ,Wi-Fi Calling and WebRTC. Despite its slow growth to date, Rich Communications Services (RCS) may turn out to be mobile operators' best-bet in offsetting the OTT competition, supported by large industry partners. Few carriers are giving enough thought to the B2B2C opportunities implicit in WebRTC and far too many continue to view the technology as a threat to their existing calling business, as opposed to an opportunity for external monetization. We believe that provisioning easy-to-access developer tools and WebRTC APIs for in-browser communications has the potential to revolutionize the carrier wholesale business on a whole new digital level.
    Request for Sample @ http://www.reportsweb.com/inquiry&RW0001130839/sample
    Key Finding
    - Telcos are focusing on Rich Communications Services (RCS) opportunity, which is charged as a premium VAS or as part of a standard mobile communications package, in order to combat the mounting mobile communications competitive pressure from OTT players. Carriers in the US, APAC and Europe are looking to align VoLTE capabilities with RCS for more advanced IP communication services.
    - Wi-Fi calling has been launched by a large number of different industry participants including mobile incumbents, cable and fixed-players, with a wide variation in use case. The operators are positioning Wi-Fi calling as a cheaper alternative for cellular calling to avoid high roaming costs and markets as coverage enhancement value-add, especially for indoor calling.
    - Companies such as Telenor, AT&T and Telefonica are experimenting with Web browser-based, real-time communications for voice and video communications. Provisioning easy-to-access developer tools and WebRTC APIs for in-browser communications has the potential to revolutionize the carrier wholesale business on a whole new digital level.
    Inquire for Discount @ http://www.reportsweb.com/inquiry&RW0001130839/discount
    Reason to Buy
    - Review technologies and services operators are deploying to compete with OTT service providers
    - Learn best practices in positioning VoLTE, RCS and Wi-Fi calling services.
    - Assess competitive products built around mesh networking.
    - Assess the various revenue models available with WebRTC APIs.
    About Us
    ReportsWeb is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Call: +1-646- 491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646- 491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Publisher's, 'Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted pipeline therapeutics.

    The report provides comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Request for Sample: http://www.reportsweb.com/Fibroblast-Growth-Factor-Receptor-4-(CD334-or-FGFR4-or-EC-2.7.10.1)---Pipeline-Review,-H2-2016

    Report Scope

    - The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
    - The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Inquire for Discount: http://www.reportsweb.com/inquiry&RW0001372933/discount

    About Us
    ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Phone: +1-646-491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Publisher's, 'Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016', provides in depth analysis on Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted pipeline therapeutics.

    The report provides comprehensive information on the Focal Adhesion Kinase (FAK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Request for Sample: http://www.reportsweb.com/Focal-Adhesion-Kinase-(FAK-or-EC-2.7.10.2)---Pipeline-Review,-H2-2016

    Report Scope

    - The report provides a snapshot of the global therapeutic landscape for Focal Adhesion Kinase (FAK or EC 2.7.10.2)
    - The report reviews Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Focal Adhesion Kinase (FAK or EC 2.7.10.2)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Focal Adhesion Kinase (FAK or EC 2.7.10.2) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Inquire for Discount: http://www.reportsweb.com/inquiry&RW0001372932/discount

    About Us
    ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Phone: +1-646-491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Cloud Services in Asia Pacific: Global Consolidation and Evolving Provider Specialization,' a Telecom Insider Report by Pyramid Research, analyzes the market for cloud services in Asia-Pacific. It provides an overview of how the cloud market is evolving in the Asia-Pacific region and in global market to cater to the rising demand of innovative cloud services. The report provides a detailed analysis of market drivers that are motivating enterprises to adopt cloud along with study of evolution of ecosystem between cloud

     



    providers and adjacent industries.

    The report is organized as follows:
    - Market context: This section examines the evolution of cloud services to meet up the rising demand by enterprises to fulfill need of their strategic engagements.
    - Market drivers: Key approaches to cloud innovation, Globally and in Asia Pacific: This section examines more specifically the markets drivers that are stirring innovation in cloud services such as economies of cloud adoption, evolving ecosystems, advancing the enterprise agenda and the quest for differentiation.
    - Market detail: Case studies: It includes four case studies explaining strategies, goals and monetization plans of cloud provider with brief about innovation in their cloud services.
    - Key findings and recommendations: This section provides the report's findings on cloud market, along with Pyramid Research's recommendations for IT and communication service providers as well as for technology vendors.

    Request for Sample @ http://www.reportsweb.com/inquiry&RW0001128323/sample

    Reason to Buy
    - This Telecom insider helps executives build proactive, profitable growth strategies by offering comprehensive, relevant analysis of the global and APAC enterprise cloud services market opportunity, competitive environment and best practices for telcos and equipment vendors.
    - The competitive landscape and the most successful strategies are given extra attention, enabling local players or prospective market entrants to gain the insight they need.
    - The broad but detailed perspective will help telcos, equipment vendors and other telecom industry players to succeed in the challenging enterprise cloud services sector across the APAC region.
    - The report is designed for an executive-level audience, boasting presentation quality that allows it to be turned into presentable material immediately.

    Inquire for Discount @ http://www.reportsweb.com/inquiry&RW0001128323/discount


    About Us
    ReportsWeb is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Call: +1-646- 491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646- 491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Publisher's, 'Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2016', provides in depth analysis on Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted pipeline therapeutics.

    The report provides comprehensive information on the Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Request for Sample: http://www.reportsweb.com/Glucocorticoid-Induced-Tumor-Necrosis-Factor-Receptor-(Activation-Inducible-TNFR-Family-Receptor-or-Glucocorticoid-Induced-TNFR-Related-Protein-or-CD357-or-TNFRSF18)---Pipeline-Review,-H1-2016

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
    - The report reviews Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Inquire for Discount: http://www.reportsweb.com/inquiry&RW0001347453/discount

    About Us
    ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Phone: +1-646-491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Publisher's, 'Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Pipeline Review, H1 2016', provides in depth analysis on Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted pipeline therapeutics.

    The report provides comprehensive information on the Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Request for Sample: http://www.reportsweb.com/Glutamate-Carboxypeptidase-2-(Folate-Hydrolase-or-Prostate-Specific-Membrane-Antigen-or-PSMA-or-Pteroylpoly-Gamma-Glutamate-Carboxypeptidase-or-EC-3.4.17.21)---Pipeline-Review,-H1-2016

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21)
    - The report reviews Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Inquire for Discount: http://www.reportsweb.com/inquiry&RW0001347488/discount

    About Us
    ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Phone: +1-646-491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Cloud Services in Europe: Trends in Ecosystem Development and Services Integration,' a Telecom Insider Report by Pyramid Research, analyzes the market for cloud services in Europe. It provides an overview of the market trends in the cloud market such as recent innovation, investments by telco and cloud service providers, increasing adoption by enterprises etc. The report provides a detailed analysis of market drivers that are accelerating adoption of cloud service and facilitating innovative in the cloud industry.

    The

     



    report is organized as follows:
    - Market context: This section examines trends in European cloud market such as investments by IT and communications service providers as well as large telcos and integrators.
    - Market drivers: Key approaches to cloud innovation: This section examines more specifically the markets drivers including development of new innovative cloud systems to meet demand by enterprises, emergence of new complex ecosystems, new role of service providers in managing and integrating IT resources for enterprises and reinvention of traditional IT apps and services for the cloud.
    - Market detail- Case studies: It includes four case studies explaining solutions, goals and monetization plans of cloud provider with brief about innovation in their cloud services.
    - Key findings and recommendations: This section provides the report's findings on cloud market, along with Pyramid Research's recommendations for IT and communication service providers as well as for technology vendors.
    Request for Sample @ http://www.reportsweb.com/inquiry&RW0001128322/sample
    Reason to Buy
    - This Telecom insider helps executives build proactive, profitable growth strategies by offering comprehensive, relevant analysis of the European enterprise cloud services market opportunity, competitive environment and best practices for telcos and equipment vendors.
    - The competitive landscape and the most successful strategies are given extra attention, enabling local players or prospective market entrants to gain the insight they need.
    - The broad but detailed perspective will help telcos, equipment vendors and other telecom industry players to succeed in the challenging enterprise cloud services sector across the European region.
    - The report is designed for an executive-level audience, boasting presentation quality that allows it to be turned into presentable material immediately.

    Inquire for Discount @ http://www.reportsweb.com/inquiry&RW0001128322/discount

    About Us
    ReportsWeb is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Call: +1-646- 491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646- 491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Mobile Data and WiFi Monetization: Convergent and user-centric offers take center stage offers a thorough examination of the main approaches and strategies being adopted by MNOs around the world to monetize mobile data. The report starts with an analysis of the business drivers of mobile data services from the providers point of view. It continues with an overview of three different types of strategic approaches to mobile data monetization being followed by service providers, including WiFI-centric models. It then provides

     



    an in-depth study of the specific mobile data strategies of specific operators in the US, the UK, Asia and Latin America, with a focus on the particular drivers and outcomes for each operator, as well as look at two WiFi models. We finish with key findings and recommendations for mobile data service providers. The Report is structured as follows:

    - Introduction: Mobile data opportunities and challenges. This section provides an overview of the growth opportunities in mobile data and the challenges faced by the operators in a changing competitive and regulatory landscape.
    - Section 1: Mobile broadband as a catalyst of growth. Here we explore four key business drivers that are generating increased focus and investments in mobile data globally.
    - Section 2: Key approaches to mobile data monetization. This section examines three different approaches to monetizing mobile data, their key elements, impact and evolution.
    - Section 3: Case studies Mobile data strategies. Each case study offers a detailed analysis of the business drivers, approach and strategies taken by the provider to monetize mobile data, as well as the business impact and outlook in mobile data. Operators featured are America Mvil, AT&T, British Telecom (EE), China Telecom, Telefnica.
    - Section 4: WiFi monetization approaches. Here we examine the evolution of commercial models for WiFi and provide case studies of two WiFi providers disrupting the space with unique models, Boingo and Google.
    - Section 5: Key findings and recommendations. We conclude with a summary of our findings on the key mobile data and WiFI monetization strategies around the world, as well as specific recommendations for network operators looking to increase their mobile data revenue.
    Report Summary
    The insatiable demand for continuous broadband connectivity has turned mobile data into a revenue growth engine for mobile network operators (MNO). Operators are exploring diverse approaches to attract users and grow mobile data revenue, including network-centric, user-centric and WiFi-centric strategies. Some leading operators are building scale and revenue share through technological and performance leadership. Other operators are leveraging their powerful user analytics capabilities to design differentiated packaging and compelling offers to drive mobile data uptake and usage. In addition, MNOs are increasingly exploiting synergies stemming from WiFi connectivity, making WiFi a key element of the mobile broadband service proposition.
    Request for Sample @ http://www.reportsweb.com/inquiry&RW00020653/sample

    Key Findings
    - Mobile broadband has become a primary revenue growth engine for MNOs around the world. Operators are responding to the mobile data opportunity with converged services portfolios and multi-play offers. Big data analytics are increasingly being leveraged to come up with accurate data pricing, bundling and marketing strategies for mobile data.
    - Mobile operators take multiple approaches to mobile data monetization. Some strategies emphasize network performance, some focus on user drivers, and some position WiFi as a core service. Network-centric monetization strategies leverage technological leadership while user-centric models focus on the needs and preferences of customers. WiFi-centric models position WiFi as a key element of the overall broadband value proposition.
    - WiFi is gaining importance among operators both as a tool to provide seamless broadband connectivity and as a services platform. Mobile network operators are leveraging WiFi to retain customers, increase their spend share and reduce network costs. While MNOs and WiFi infrastructure providers expand their WiFi hotspot footprint, emerging models such as WiFi First are changing the rules of the game.
    Inquire for Discount @ http://www.reportsweb.com/inquiry&RW00020653/discount
    Reason to Buy
    - Mobile Data and WiFi Monetization: Convergent and user-centric offers take center stage provides a comprehensive analysis of key monetization models and market strategies for mobile data that are being employed across the world, helping executives at MNOs, fixed telcos and pay-TV providers make informed strategic decisions. By understanding the approaches and successful strategies of leading market players, telecom executives can formulate strategies to retain customers, generate revenue growth and navigate safely in the face of disruptive competition.
    - The reports forward-looking analysis of key business drivers and monetization models for mobile data helps providers assess the potential impact of mobile data on their business and identify related opportunities. The case studies focus on how mobile operators and WiFi providers in 5 developed and emerging markets are tapping the mobile broadband opportunity, allowing executives to refine their strategies.
    - The reports recommendations are based on real strategies employed by network operators to position themselves to take advantage of the mobile data revenue opportunity and increase their participation in the mobile broadband services space. Network operators can benefit from strategies such as leveraging big data to design user-centric offers and positioning WiFi as a key tool for sustainable customer satisfaction and revenue growth.
    About Us
    ReportsWeb is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Call: +1-646- 491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646- 491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Pyramid's Mobile Money - Emerging Trends, Growth Drivers and Future Outlook report examines executives' opinion on key drivers of mobile money usage and trends likely to influence mobile money during the next two years. It also highlights regional growth outlook, investment projections, revenue share expectations, major challenges and growth prospects of specific product offerings. Additionally, it provides information categorized by region and company type.

    What else does this report offer?
    - Mobile money product

     



    adoption status: highlights organizations position on mobile money product offerings
    - Projected change in investment: examines anticipated change in expenditure on mobile money services over the next two years
    - Revenue share expectations: analyzes telecom industry executives' opinion on revenue share contribution by mobile money during the next two years
    - Key drivers: identifies major factors influencing mobile money usage in the coming two years
    - Future impacting trends: provides information about Trends likely to influence mobile money over the next two years
    - Growth prospects of product offerings: evaluates how growth outlook of mobile money product range will change during the next two years
    - Regional growth outlook: indicates growth prospects for mobile money across regions in the coming two years
    - Barriers towards future growth: determines challenges expected to inhibit growth prospects of mobile money over the next two years.
    Request for Sample @ http://www.reportsweb.com/inquiry&RW0001122504/sample
    Report Summary
    Even though organizations within telecom industry are concerned about security and privacy issues and lack of awareness about mobile money, increasing penetration of smartphones and internet, preference for cashless transactions and growing e-commerce will push mobile money usage over the next two years. Globally, investment on mobile money services is anticipated to increase by 22.2% during the next two years which will result in revenue share of mobile money reaching towards 9% in the coming two years. Asia and Africa are expected to offer significant growth for mobile money over the next two years with technological innovation and focus on interoperability emerging as prominent trends.
    Inquire for Discount @ http://www.reportsweb.com/inquiry&RW0001122504/discount
    Reason To Buy
    - Highlights trends which will impact mobile money future prospects thus helping telecom organizations to realign business strategy
    - Assist in development or adjustment of business expansion plans by providing information about regional growth outlook
    - Helps organizations to overcome obstacles by indicating challenges expected to inhibit growth prospects of mobile money over the next two years
    - Highlights growth prospects of product offerings over the next two years thus allowing organizations to boost revenues by focusing on select products
    About Us
    ReportsWeb is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
    Contact Us:
    Call: +1-646- 491-9876
    Email: sales@reportsweb.com



    Priya Sisodia
    +1-646- 491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Sample/TOC request, please email : phoebe@qyresearch.com

    Report summery

    The report provides a basic overview of the GNSS industry including definitions, classifications, applications and industry chain structure.

    Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand figures, cost, price, revenue and gross margins.

    The report then analyzes the global GNSS market size (volume and

     



    value), and the sales segment market is also discussed by product type, application and region.

    The major GNSS market (including USA, Europe, China, Japan, etc.) is analyzed, data including: market size, import and export, sale segment market by product type and application. Then we forecast the 2016-2021 market size of GNSS.

    The report focuses on global major leading companies providing information such as company profiles, sales, sales revenue, market share and contact information. Then the GNSS OEM market and GNSS production market status is discussed.

    Finally the marketing, feasibility of new investment projects are assessed and overall research conclusions offered.



    Players covering

    Qualcomm

    Trimble Navigation

    Broadcom

    CSR(Qualcomm)

    Laird PLC

    Furuno Electric

    Rockwell Collins

    Texas Instruments

    Cobham

    Hexagon

    Garmin

    General Motors

    Hemisphere GNSS

    Ford

    Apple

    Nissan

    Rockwell Collins

    Volkswagen

    Toyota

    BMW

    Intel Corporation

    Honda

    China First Automob.

    AgJunction

    Caterpillar

    NovAtel

    ...

    Part of the Catalog for reference:

    1 GNSS Overview

    1.1 Product Overview and Scope of GNSS

    1.2 Classification of GNSS

    1.2.1 GPS

    1.2.2 Glonass

    1.2.3 Galileo

    1.2.4 BDS

    1.3 Application of GNSS

    1.3.1 Location-Based Services (LBS)

    1.3.2 Road

    1.3.3 Aviation

    1.3.4 Rail

    1.3.5 Others

    1.4 GNSS Market by Regions

    1.4.1 USA Status and Prospect (2011-2021)

    1.4.2 China Status and Prospect (2011-2021)

    1.4.3 Europe Status and Prospect (2011-2021)

    1.4.4 Japan Status and Prospect (2011-2021)

    1.4.5 India Status and Prospect (2011-2021)

    1.4.6 Southeast Asia Status and Prospect (2011-2021)

    1.5 Global Market Size (Value and Volume) of GNSS (2011-2021)

    1.5.1 Global GNSS Sales and Growth Rate (2011-2021)

    1.5.2 Global GNSS Revenue and Growth Rate (2011-2021)



    2 Global GNSS Competition by Manufacturers, Type and Application

    2.1 Global GNSS Market Competition by Manufacturers

    2.1.1 Global GNSS Sales and Market Share of Key Manufacturers (2011-2016)

    2.1.2 Global GNSS Revenue and Share by Manufacturers (2011-2016)

    2.2 Global GNSS (Volume and Value) by Type

    2.2.1 Global GNSS Sales and Market Share by Type (2011-2016)

    2.2.2 Global GNSS Revenue and Market Share by Type (2011-2016)

    2.3 Global GNSS (Volume and Value) by Regions

    2.3.1 Global GNSS Sales and Market Share by Regions (2011-2016)

    2.3.2 Global GNSS Revenue and Market Share by Regions (2011-2016)

    2.4 Global GNSS (Volume) by Application

    ...

    Contact me:

    QYRESEARCH CO., LTD

    VILI International Building No.167 Linhe West Road Tianhe District Guangzhou China

    Phoebe Lee - QYResearch Report Global Sales

    Email: phoebe@qyresearch.com phoebe@qyresearchglobal.com

    Web: http://qyresearchglobal.com/ http://qyresearcheurope.com/




    qyresearch global
    862086655165
    phoebe@qyresearch.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, September 29, 2016 ) Sample/TOC request, please email : phoebe@qyresearch.com

    Report summery

    The report provides a basic overview of the Kombucha industry including definitions, classifications, applications and industry chain structure.

    Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand figures, cost, price, revenue and gross margins.

    The report then analyzes the global Kombucha market size (volume

     



    and value), and the sales segment market is also discussed by product type, application and region.

    The major Kombucha market (including USA, Europe, China, Japan, etc.) is analyzed, data including: market size, import and export, sale segment market by product type and application. Then we forecast the 2016-2021 market size of Kombucha.

    The report focuses on global major leading companies providing information such as company profiles, sales, sales revenue, market share and contact information. Then the Kombucha OEM market and Kombucha production market status is discussed.

    Finally the marketing, feasibility of new investment projects are assessed and overall research conclusions offered.



    Players covering

    Synergy Drinks

    Humm Kombucha

    Kombucha Wonder Drink

    Pronatura

    Yogi

    Kombucha Brooklyn

    Scoby Kombucha

    Andalou Naturals

    Get Kombucha

    Mortier Pilon

    Kehe Distributors

    Garden of Life

    Swanson Origanic

    ...

    Part of the Catalog for reference:

    1 Kombucha Overview

    1.1 Product Overview and Scope of Kombucha

    1.2 Classification of Kombucha

    1.2.1 Type I

    1.2.2 Type II

    1.2.3 Type III

    1.3 Application of Kombucha

    1.3.1 Application 1

    1.3.2 Application 2

    1.3.3 Application 3

    1.4 Kombucha Market by Regions

    1.4.1 USA Status and Prospect (2011-2021)

    1.4.2 China Status and Prospect (2011-2021)

    1.4.3 Europe Status and Prospect (2011-2021)

    1.4.4 Japan Status and Prospect (2011-2021)

    1.4.5 India Status and Prospect (2011-2021)

    1.4.6 Southeast Asia Status and Prospect (2011-2021)

    1.5 Global Market Size (Value and Volume) of Kombucha (2011-2021)

    1.5.1 Global Kombucha Sales and Growth Rate (2011-2021)

    1.5.2 Global Kombucha Revenue and Growth Rate (2011-2021)



    2 Global Kombucha Competition by Manufacturers, Type and Application

    2.1 Global Kombucha Market Competition by Manufacturers

    2.1.1 Global Kombucha Sales and Market Share of Key Manufacturers (2011-2016)

    2.1.2 Global Kombucha Revenue and Share by Manufacturers (2011-2016)

    2.2 Global Kombucha (Volume and Value) by Type

    2.2.1 Global Kombucha Sales and Market Share by Type (2011-2016)

    2.2.2 Global Kombucha Revenue and Market Share by Type (2011-2016)

    2.3 Global Kombucha (Volume and Value) by Regions

    2.3.1 Global Kombucha Sales and Market Share by Regions (2011-2016)

    2.3.2 Global Kombucha Revenue and Market Share by Regions (2011-2016)

    2.4 Global Kombucha (Volume) by Application

    ...

    Contact me:

    QYRESEARCH CO., LTD

    VILI International Building No.167 Linhe West Road Tianhe District Guangzhou China

    Phoebe Lee - QYResearch Report Global Sales

    Email: phoebe@qyresearch.com phoebe@qyresearchglobal.com

    Web: http://qyresearchglobal.com/ http://qyresearcheurope.com/






    qyresearch global
    862086655165
    phoebe@qyresearch.com

    Source: EmailWire.Com